Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND Excess aldosterone accelerates chronic kidney disease progression. This phase 2 clinical trial assessed BI 690517, an aldosterone synthase inhibitor, for efficacy, safety, and dose selection. METHODS This was a multinational, randomised, controlled, phase 2 trial. People aged 18 years or older with an estimated glomerular filtration rate (eGFR) of 30 to less than 90 mL/min/1·73 m2, a urine albumin to creatinine ratio (UACR) of 200 to less than 5000 mg/g, and serum potassium of 4·8 mmol/L or less, taking an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, were enrolled. Participants were randomly assigned (1:1) to 8 weeks of empagliflozin or placebo run-in, followed by a second randomisation (1:1:1:1) to 14 weeks of treatment with once per day BI 690517 at doses of 3 mg, 10 mg, or 20 mg, or placebo. Study participants, research coordinators, investigators, and the data coordinating centre were masked to treatment assignment. The primary endpoint was the change in UACR measured in first morning void urine from baseline (second randomisation) to the end of treatment. This study is registered with ClinicalTrials.gov (NCT05182840) and is completed. FINDINGS Between Feb 18 and Dec 30, 2022, of the 714 run-in participants, 586 were randomly assigned to receive BI 690517 or placebo. At baseline, 33% (n=196) were women, 67% (n=390) were men, 42% (n=244) had a racial identity other than White, and mean participant age was 63·8 years (SD 11·3). Mean baseline eGFR was 51·9 mL/min/1·73 m2 (17·7) and median UACR was 426 mg/g (IQR 205 to 889). Percentage change in first morning void UACR from baseline to the end of treatment at week 14 was -3% (95% CI -19 to 17) with placebo, -22% (-36 to -7) with BI 690517 3 mg, -39% (-50 to -26) with BI 690517 10 mg, and -37% (-49 to -22) with BI 690517 20 mg monotherapy. BI 690517 produced similar UACR reductions when added to empagliflozin. Investigator-reported hyperkalaemia occurred in 10% (14/146) of those in the BI 690517 3 mg group, 15% (22/144) in the BI 690517 10 mg group, and 18% (26/146) in the BI 690517 20 mg group, and in 6% (nine of 147) of those receiving placebo, with or without empagliflozin. Most participants with hyperkalaemia did not require intervention (86% [72/84]). Adrenal insufficiency was an adverse event of special interest reported in seven of 436 study participants (2%) receiving BI 690517 and one of 147 participants (1%) receiving matched placebo. No treatment-related deaths occurred during the study. INTERPRETATION BI 690517 dose-dependently reduced albuminuria with concurrent renin-angiotensin system inhibition and empagliflozin, suggesting an additive efficacy for chronic kidney disease treatment without unexpected safety signals. FUNDING Boehringer Ingelheim.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heerspink, H. J. L., Greene, T., Tighiouart, H., Gansevoort, R. T., Coresh, J., Simon, A. L., Chan, T. M., Hou, F. F., Lewis, J. B., Locatelli, F., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30314-0 · Cited by 397
Self-citationRossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.013 · Cited by 274
Self-citationAldosterone synthase inhibitors in cardiovascular and renal diseases
Namsolleck, P., & Unger, T. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft402 · Cited by 63
Research works printed but not linked: 27
- Jager, 2019, A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases, Nephrol Dial Transplant, 34, 1803, 10.1093/ndt/gfz174 · DOI · Paper page
- Evans, 2022, A narrative review of chronic kidney disease in clinical practice: current challenges and future perspectives, Adv Ther, 39, 33, 10.1007/s12325-021-01927-z · DOI · Paper page
- Tuttle, 2022, Molecular mechanisms and therapeutic targets for diabetic kidney disease, Kidney Int, 102, 248, 10.1016/j.kint.2022.05.012 · DOI · Paper page
- Epstein, 2021, Aldosterone and mineralocorticoid receptor signaling as determinants of cardiovascular and renal injury: from hans selye to the present, Am J Nephrol, 52, 209, 10.1159/000515622 · DOI
- Verma, 2022, Aldosterone in chronic kidney disease and renal outcomes, Eur Heart J, 43, 3781, 10.1093/eurheartj/ehac352 · DOI
- Zhong, 2017, A perspective on chronic kidney disease progression, Am J Physiol Renal Physiol, 312, F375, 10.1152/ajprenal.00266.2016 · DOI
- Rossignol, 2019, Recurrent hyperkalaemia management and use of renin-angiotensin-aldosterone system inhibitors: a European multi-national targeted chart review, Clin Kidney J, 13, 714, 10.1093/ckj/sfz129 · doi:10.1093/ckj/sfz129
- Epstein, 2022, Aldosterone, mineralocorticoid receptor activation, and CKD: a review of evolving treatment paradigms, Am J Kidney Dis, 80, 658, 10.1053/j.ajkd.2022.04.016 · DOI
- Gilligan, 2017, Hyperkalemia and hypokalemia in CKD: prevalence, risk factors, and clinical outcomes, Adv Chronic Kidney Dis, 24, 315, 10.1053/j.ackd.2017.06.004 · DOI
- Rossignol, 2020, Recurrent hyperkalaemia management and use of renin-angiotensin-aldosterone system inhibitors: a European multi-national targeted chart review, Clin Kidney J, 13, 714, 10.1093/ckj/sfz129 · doi:10.1093/ckj/sfz129
- Hargovan, 2014, Aldosterone synthase inhibitors in hypertension: current status and future possibilities, JRSM Cardiovasc Dis, 3
- Andersen, 2012, The effects of aldosterone synthase inhibition on aldosterone and cortisol in patients with hypertension: a phase II, randomized, double-blind, placebo-controlled, multicenter study, J Clin Hypertens (Greenwich), 14, 580, 10.1111/j.1751-7176.2012.00667.x · DOI · Paper page
- Lu, 2010, Aldosterone in the pathogenesis of chronic kidney disease and proteinuria, Curr Hypertens Rep, 12, 303, 10.1007/s11906-010-0116-4 · DOI
- Frimodt-Møller, 2020, Mitigating risk of aldosterone in diabetic kidney disease, Curr Opin Nephrol Hypertens, 29, 145, 10.1097/MNH.0000000000000557 · DOI
- Azizi, 2013, Aldosterone synthase inhibition in humans, Nephrol Dial Transplant, 28, 36, 10.1093/ndt/gfs388 · DOI
- Tuttle, 2023, Study design and baseline characteristics for aldosterone synthase inhibition in CKD, Am J Nephrol
- Rossing, 2022, Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis, Diabetes Care, 45, 2991, 10.2337/dc22-0294 · DOI · Paper page
- Provenzano, 2021, The kidney protective effects of the sodium-glucose cotransporter-2 inhibitor, dapagliflozin, are present in patients with CKD treated with mineralocorticoid receptor antagonists, Kidney Int Rep, 7, 436, 10.1016/j.ekir.2021.12.013 · DOI
- Jongs, 2021, Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial, Lancet Diabetes Endocrinol, 9, 755, 10.1016/S2213-8587(21)00243-6 · DOI · Paper page
- Goulooze, 2022, Dose-exposure-response analysis of the nonsteroidal mineralocorticoid receptor antagonist finerenone on UACR and eGFR: an analysis from FIDELIO-DKD, Clin Pharmacokinet, 61, 1013, 10.1007/s40262-022-01124-3 · DOI
- Ferreira, 2021, Aldosterone, inflammation, immune system, and hypertension, Am J Hypertens, 34, 15, 10.1093/ajh/hpaa137 · DOI · Paper page
- Butt, 2020, A molecular mechanism explaining albuminuria in kidney disease, Nat Metab, 2, 461, 10.1038/s42255-020-0204-y · DOI · Paper page
- Freeman, 2023, Phase 2 trial of baxdrostat for treatment-resistant hypertension, N Engl J Med, 388, 395, 10.1056/NEJMoa2213169 · DOI · Paper page
- Laffin, 2023, Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: the target-HTN randomized clinical trial, JAMA, 330, 1140, 10.1001/jama.2023.16029 · DOI · Paper page
- Agarwal, 2019, Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial, Lancet, 394, 1540, 10.1016/S0140-6736(19)32135-X · DOI · Paper page
- Neuen, 2022, Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials, Circulation, 145, 1460, 10.1161/CIRCULATIONAHA.121.057736 · DOI · Paper page
- Ferreira, 2022, Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled, Eur Heart J, 43, 2984, 10.1093/eurheartj/ehac306 · DOI
Cited by
Apperloo, E. M., Gorriz, J. L., Soler, M. J., Cigarrán Guldris, S., Cruzado, J. M., Puchades, M. J., López-Martínez, M., Waanders, F., Laverman, G. D., van der Aart-van der Beek, A., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03327-6 · Cited by 120
Self-citation
Metadata
- Authors
- Tuttle, K. R., Hauske, S. J., Canziani, M. E., Caramori, M. L., Cherney, D., Cronin, L., Heerspink, H. J. L., Hugo, C., Nangaku, M., Rotter, R. C., Silva, A., Shah, S. V., Sun, Z., Urbach, D., de Zeeuw, D., Rossing, P., Tuttle, K. R., Hauske, S. J., Canziani, M. E., Caramori, M. L., Cherney, D., Cronin, L., Heerspink, H. J. L., Hugo, C., Nangaku, M., Rotter, R. C., Silva, A., Shah, S. V., Sun, Z., Urbach, D., de Zeeuw, D., Rossing, P., SZETO, C. C., Echeverri, D., Martin, E., Yee, M. L., Wah, W., Wang, R., Chacko, B., Swaminathan, S., MacIsaac, R., Hashimura, H., Ward, G., De Vusser, K., Claes, K., Kuypers, D., Meijers, B., Van Craenenbroeck, A., Hilbrands, R., Debroye, C., Wissing, K. M., Jadoul, M., Demoulin, N., Treille De Grandsaigne, S., Beklevic, I., Marcoux, D., Liénart, F., Daper, C., De Brouckere, V., Heureux, M., Felicio, J., Felicio, K. M., Leite, D., Melo, F., Queiroz, N., Souza, A. C., Vieira, J., Franco, R., Mendes, A., Picolli, G., Canani, L. H., Sartori, C., Valenti, A., Eliaschewitz, F., Bona, R., Franco, D., Ludovico Costa de Castro, D., Magalhaes, V., Oliveira, M., Sampaio, C. R., Visconti, G., Halpern, B., Nihei, C., Pessoa, B., Seraphim, C., Santos, D., Brito, C., Douverny, J., Colella, M., Gazeta, C., Vercia, M., Watanabe, R., Temelkova, T., Kjurkchiev, D., Statkova, S., Popov, I., Radeva, R., Arabadzhiev, L., Binova, M., Bosilkov, A., Koleva-Stoicheva, N., Ivanov, I., Ivanova, Z., Kotseva, V., Spasov, P., Tsvetkov, I., Jolly, S., Bailey, G., Ye, Z., Niu, J., Li, H., Wu, Q., Liao, B., Hao, C., Lai, L., Xu, Y., Zhang, M., Li, Y., Liu, B., Shao, L., Chen, W., Wu, H., Pirchala, M., Skarpova, I., Hraskova, M., Soukupova, S., Veberova, L., Drasnar, T., Falc, M., Racz, B., Votocek, S., Weissova, D., Syc-Krivanova, L., Slezak, D., Kantola, I., Nieminen, S., Anttonen, M., Taurio, J., Lahtela, J., Tsimihodimos, V., Balafa, O., Dounousi, E., Sakkou, S., Tentolouris, N., Siafarikas, C., Siami, E., Doupis, I., Angelopoulos, T., Georgoulias, C., Pall, D., Esze, R., Kobling, T., Varadi, Z., Zsiros, N., Vass, V., Balo, T., Csanyi, E., Ory, I., Pall, I., Patai, V., Zeak, Z., Takacs, I., Petho, A., Szili, B., Koranyi, L., Bezzegh, K., Pauer, J., Peterfai, E., Konyves, L., Szoke, B., Hajdu, C., Kalman, K., Yadav, R., Saxena, N., Bhattacharya, M., Sharma, B., Thomas, N., K, F. J., Kapoor, N., Kurian, M. E., Paul, J., Ramesh, P., Varghese, S., Shibusawa, N., Nishi, H., Noritake, N., Oda, T., Okamoto, H., Kasuga, H., Hori, H., Ito, Y., Mizukoshi, T., Ishii, H., Han, S. H., Kim, H. W., Oh, K.-H., Han, S. S., Han, S. Y., Cha, D. R., Cha, J. J., Kwon, S.-K., Cho, H., Kim, H.-Y., Kim, S. M., Lee, J. P., Lee, J., Lee, L. Y., Chang, M. L., Laang, S. T., Tan, Z. Z., Ahmad Rosdi, H., Mohammad Ismail, S. H., Simatherai, D., Tay, J. F., Wong, E., Yakob, S., Abdul Sukur, N., Anuar, A., Md. Rasid, S., Mushaddik, I. L., Mustafar, R., Abu Shamsi, M. Y., Fong, V. K., Kamaruzaman, L., Mohd, R., Wan Daud, W. R., Wan Hassan, W. H. H., Ab Hamid, S., Abdullah, M. N., Yusoff, M. Y., Ramanathan, G. R. L., Lee, K. Y., Wan Ismail, W. F., Morales Villegas, E., Ramirez Baez, R., Vital Lopez, J., Arias Delgadillo, C., Herrera Marmolejo, M., Parra Perez, R., Alpizar Salazar, M., Flores Montealegre, A., Galvan Magaña, J., Gutierrez Tlapale, M., Reyes Munguia, D., Witczak, B., Gøransson, L., Strand Thorsen, I., Caringal, C., Villardo, M., Toledo, R., Dijamco, E. F., De Asis, N. C., Kuizon, A., Catindig, E. A., Perez, R., Aquitania, G., Pableo, J. D., Sanchez, J. K., Czernecka, E., Cegiel, A., Knychas, D., Ochnio, M., Kuligowska-Jakubowska, M., Cesarz, M., Kowalewska-Celejewska, M., Masajtis-Zagajewska, A., Jankowski, L., Ojrzanowski, M., Olszewska-Jander, M., Skokowska, E., Giermakowska-Samek, M., Luchowska, E., Patkowska, R., Sekulska, M., Marczuk-Krynicka, D., Marciniak, A., Barwijuk, M., Myslicki, M., Siek, M., Wronska, D., Tomsia-Goncerz, J., Wronski, K., Junik, R., Dzialak, S., Kurlapska, E., Malecha, W., Suwala, S., Branco, P., Birne, R., Raposo, J., Ferreira, M., Alexandrino, H., Alves, H., Correia, S., Oliveira, M. J., Ramalho, D., Tavares, P., Coetzee, K., Blignaut, S., Viljoen, W., Potgieter, E., Malherbe, E., Ortiz Arduán, A., Goma Garcés, E., Pérez, M., Santamaría, R., López López, I., Pendón de Mier, V., Rodelo Haad, C., Marques, M., Domènech, E., Portoles, J. M., Soler, M. J., Agraz, I., Azancot, M. A., Bermejo, S., Bolufer, M., López, M., Ramos, N., Toapanta, N., Cigarrán Guldris, S., Primo, J. C., Pérez, L. E., Rebollido Fernández, M., Holmer, H., Bruchfeld, A., Rofors, J., Tengmark, B.-O., Wuerzner, G., Leanizbarrutia, G., Ozturk, S., Guler, N., Safak, S., Lee, K., Campbell, S., Siddiqui, I., Abbasi, N., Tahir, F., Azizad, M., Jackson, T., Everhart, B., Oliver, M., Rust, W., Sniezek, M., Arif, A., Syed, M., Bhasin, N., Bien, M., Gallego, C., Jamal, A., Moghadam, M., Rizvi, A., Rizvi, A., Rizvi, S., Wong, C., Lucas, K., Buery, A., Chang, K.-L., Presswood, C., Smith, J., Doshi, A., Parikh, M., Wallace, J., Krishna, A., Daugherty, H., Fearday, A., Keller, C., Meng, J., Nielsen, A., Rovner, S., Almeida, J., Marranzini, B., Selby, L., Yablon, Z., Jean-Louis, D., Kotzker, W., Perez, C., Richards, M., Rosario, R., Marcus, R., Okechukwu, C., Ross, D., Gromala, R., Reed, M., Weber, L., Nazeer, I., Kumar, P., Mir, M., Shea, H., Hart, A., Wiebel, J., Kooienga, L., Newsome, B., Suyumova, I., Alvarez, G., Bireddy, V., Lansang, M., Mandry, J., Freire, M., Herrera Albornoz, O., Desai, A., Gandhi, D., Rajan, S., Raymond, L., Posada, J., Garcia-Mayol, L., Gutierrez-Alsina, R., Fernandez, J., Bruce, K., Cuellar, J., Ranz y Alvarez, M., Bartolacci, I., Pautasso, M., Stoppa, D., Riella, M., Barbosa, M., Harcsa, E., Gulati, Y., Savalia, D., Khetan, P., Sinha, D., R, N., K, S., Pazos, F., Gacutan-Liwag, A., Duszynska, M., Antkowiak-Piatyszek, K., Konieczny, G., Sidorowicz-Bialynicka, A., Ciesiolkiewicz-Wojcik, A., Dwojak, M., Szymkowiak, K., Gorczyca-Siudak, D., Janik-Palazzolo, M., Siudak, L., Opiela, J., Iwanow, D., Solkiewicz, M., Sipinska-Surzynska, M., Olszanecka - Glinianowicz, M., Rozmilowska, I., Trokis, J., Prozesky, H., Burgess, L., Cyster, H., Jordaan, J., Mohamed, H., Naude, C., Sitsila, T., Mehta, A., Mocherla, B., Lee, S., Boren, K., Rudolph, L., Benjamin, S., Sugimoto, D., Hammoud, J., Bakleh, M., Hashish, Y., Da Costa, J., Gold, M., Majul, C., Buscema, J., Gatto, M., Lombardi, F., Paez, O., Puleio, P., Alvarisqueta, A., Pajon, V., Suarez, G., Hernandez Gauna, A., Pereyra, A., Reig, M., Gelersztein, E., Campestri, G., Gonzalez Santos, M., Sambresqui, J., Catalano, G., Igarzabal, C., Vallejos, A., Escobari, C., Marchetto, R., Chahin, M., Aguilera, A., Comes, A., Rodriguez Segade, S., Baccaro, C., Larrieu Lacoste, M. V., Saurral, R., Cristino, A., Dran, D., Koretzky, M., Ponti, J., Porto, A., Tenaglia, Y., Maldonado, N., Bertollo, N., Van Perdeck, V., Lopau, K., Wanner, C., Berfelo, F., Contzen, C., Arbi, A., Lee-Barkey, Y. H., Maciejewska, A., Arelin, K., Haller, H., Kaufeld, J., Schmidt-Ott, K., Heinrichs, S., Krüger, T., Gebauer, C., Paliege, A., Henkel, E., Axthelm, C., Derwahl, K.-M., Trevisan, R., Bellante, R., Borrella, N., Corsi, A., Gesualdo, L., Ardillo, T., Ficarella, M., Fikry, S., Mazza, G., Poirier, L., Bajaj, H., Hatziagelaki, E., Katopodis, S., Katsoudas, S., Yamaura, S., Shikano, T., Tosaki, T., Miho, O., Tachibana, N., Yumita, W., Kado, H., Villarreal Martinez, J., Soto Miranda, E., Gonzalez Rodriguez, D., Panelo, A., Santos, T., Birne, R., Branco, P., Martins, A., Mateus, C., Teixeira e Costa, F., Barreto, S., Silva Costa, J., Ferrer, F., Silva, J., Awad, A., Khaleel, S., Lustig, R., Maharjan, G., Moya, J., Johnsingh, A., Acosta, I., Newman, G., Buckle, A., & Hendon, K.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2024-01
- Volume
- 403
- Issue
- 10424
- Pages
- 379-390
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4389774725
- Cited by
- 206
- References
- 3
- FWCI
- 34.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Funders
- Boehringer Ingelheim International GmbH
- Boehringer Ingelheim
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(23)02408-x
- The paper
- Tuttle, K. R., Hauske, S. J., Canziani, M. E., Caramori, M. L., Cherney, D., Cronin, L., Heerspink, H. J. L., Hugo, C., Nangaku, M., Rotter, R. C., Silva, A., Shah, S. V., Sun, Z., Urbach, D., de Zeeuw, D., Rossing, P., Tuttle, K. R., Hauske, S. J., Canziani, M. E., . . . Hendon, K. (2024). Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial. The Lancet. https://doi.org/10.1016/s0140-6736(23)02408-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.